Drug-coated balloon (DCB) angioplasty with rescue stenting demonstrated inferior outcomes compared with upfront drug-eluting stent (DES) implantation for de novo coronary artery disease (CAD) at 3-year follow-up, driven primarily by increased target lesion revascularization (TLR) rates.